Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL(37)) in normal mice

Nigel Irwin, BD Green, Victor Gault, RS Cassidy, Finbarr O'Harte, P Harriott, Peter Flatt

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) is a key hormone of the enteroinsular axis. The present study was designed to assess the metabolic effects in healthy mice of long term activation of the GIP receptor by N-AcGlp(LySpAL(37)), a potent long-acting GIP receptor agonist. Daily injection of N-AcGIP(LysPAL(37)) (25 nmoVkg body weight) for 14 days had no significant effect on food intake, body weight, glycated hemoglobin levels, non-fasting plasma glucose and insulin concentrations compared to saline treated controls. No significant differences in post-prandial plasma glucose and insulin concentrations were observed between the two groups following 15 min feeding. However, after 14 days, the glycemic response to intraperitoneal (i.p.) glucose was significantly improved in the NAcGIP(LysPAL(37)) treated mice compared to controls (P <0.01). In keeping with this, glucose-mediated insulin secretion was significantly enhanced in the N-AcGIP(LyspAL(37)) treated group (P <0.05). No changes in insulin sensitivity or pancreatic insulin content of the NAcGIP(LysPAL(37)) treated mice were detected. No adverse reactions were noted and the effects of N-AcGIP(LysPAL(37)) were reversed by 14 days cessation of treatment. These data indicate that long term activation of the GIP receptor by daily treatment with N-AcGIP(LysPAL(37)) improved glucose tolerance due to enhancement of pancreatic beta cell glucose responsiveness and insulin secretion. (c) 2005 Elsevier Inc. All rights reserved.
LanguageEnglish
Pages893-900
JournalPeptides
Volume27
Issue number4
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Homeostasis
Insulin
Glucose
Body Weight
Withholding Treatment
Glycosylated Hemoglobin A
Insulin-Secreting Cells
gastric inhibitory polypeptide receptor
Meals
Insulin Resistance
Eating
Hormones
Peptides
Injections

Cite this

@article{fcb39f4262aa4912acdb78423661a831,
title = "Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL(37)) in normal mice",
abstract = "Glucose-dependent insulinotropic polypeptide (GIP) is a key hormone of the enteroinsular axis. The present study was designed to assess the metabolic effects in healthy mice of long term activation of the GIP receptor by N-AcGlp(LySpAL(37)), a potent long-acting GIP receptor agonist. Daily injection of N-AcGIP(LysPAL(37)) (25 nmoVkg body weight) for 14 days had no significant effect on food intake, body weight, glycated hemoglobin levels, non-fasting plasma glucose and insulin concentrations compared to saline treated controls. No significant differences in post-prandial plasma glucose and insulin concentrations were observed between the two groups following 15 min feeding. However, after 14 days, the glycemic response to intraperitoneal (i.p.) glucose was significantly improved in the NAcGIP(LysPAL(37)) treated mice compared to controls (P <0.01). In keeping with this, glucose-mediated insulin secretion was significantly enhanced in the N-AcGIP(LyspAL(37)) treated group (P <0.05). No changes in insulin sensitivity or pancreatic insulin content of the NAcGIP(LysPAL(37)) treated mice were detected. No adverse reactions were noted and the effects of N-AcGIP(LysPAL(37)) were reversed by 14 days cessation of treatment. These data indicate that long term activation of the GIP receptor by daily treatment with N-AcGIP(LysPAL(37)) improved glucose tolerance due to enhancement of pancreatic beta cell glucose responsiveness and insulin secretion. (c) 2005 Elsevier Inc. All rights reserved.",
author = "Nigel Irwin and BD Green and Victor Gault and RS Cassidy and Finbarr O'Harte and P Harriott and Peter Flatt",
year = "2006",
month = "4",
doi = "10.1016/j.peptides.2005.08.003",
language = "English",
volume = "27",
pages = "893--900",
number = "4",

}

TY - JOUR

T1 - Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL(37)) in normal mice

AU - Irwin, Nigel

AU - Green, BD

AU - Gault, Victor

AU - Cassidy, RS

AU - O'Harte, Finbarr

AU - Harriott, P

AU - Flatt, Peter

PY - 2006/4

Y1 - 2006/4

N2 - Glucose-dependent insulinotropic polypeptide (GIP) is a key hormone of the enteroinsular axis. The present study was designed to assess the metabolic effects in healthy mice of long term activation of the GIP receptor by N-AcGlp(LySpAL(37)), a potent long-acting GIP receptor agonist. Daily injection of N-AcGIP(LysPAL(37)) (25 nmoVkg body weight) for 14 days had no significant effect on food intake, body weight, glycated hemoglobin levels, non-fasting plasma glucose and insulin concentrations compared to saline treated controls. No significant differences in post-prandial plasma glucose and insulin concentrations were observed between the two groups following 15 min feeding. However, after 14 days, the glycemic response to intraperitoneal (i.p.) glucose was significantly improved in the NAcGIP(LysPAL(37)) treated mice compared to controls (P <0.01). In keeping with this, glucose-mediated insulin secretion was significantly enhanced in the N-AcGIP(LyspAL(37)) treated group (P <0.05). No changes in insulin sensitivity or pancreatic insulin content of the NAcGIP(LysPAL(37)) treated mice were detected. No adverse reactions were noted and the effects of N-AcGIP(LysPAL(37)) were reversed by 14 days cessation of treatment. These data indicate that long term activation of the GIP receptor by daily treatment with N-AcGIP(LysPAL(37)) improved glucose tolerance due to enhancement of pancreatic beta cell glucose responsiveness and insulin secretion. (c) 2005 Elsevier Inc. All rights reserved.

AB - Glucose-dependent insulinotropic polypeptide (GIP) is a key hormone of the enteroinsular axis. The present study was designed to assess the metabolic effects in healthy mice of long term activation of the GIP receptor by N-AcGlp(LySpAL(37)), a potent long-acting GIP receptor agonist. Daily injection of N-AcGIP(LysPAL(37)) (25 nmoVkg body weight) for 14 days had no significant effect on food intake, body weight, glycated hemoglobin levels, non-fasting plasma glucose and insulin concentrations compared to saline treated controls. No significant differences in post-prandial plasma glucose and insulin concentrations were observed between the two groups following 15 min feeding. However, after 14 days, the glycemic response to intraperitoneal (i.p.) glucose was significantly improved in the NAcGIP(LysPAL(37)) treated mice compared to controls (P <0.01). In keeping with this, glucose-mediated insulin secretion was significantly enhanced in the N-AcGIP(LyspAL(37)) treated group (P <0.05). No changes in insulin sensitivity or pancreatic insulin content of the NAcGIP(LysPAL(37)) treated mice were detected. No adverse reactions were noted and the effects of N-AcGIP(LysPAL(37)) were reversed by 14 days cessation of treatment. These data indicate that long term activation of the GIP receptor by daily treatment with N-AcGIP(LysPAL(37)) improved glucose tolerance due to enhancement of pancreatic beta cell glucose responsiveness and insulin secretion. (c) 2005 Elsevier Inc. All rights reserved.

U2 - 10.1016/j.peptides.2005.08.003

DO - 10.1016/j.peptides.2005.08.003

M3 - Article

VL - 27

SP - 893

EP - 900

IS - 4

ER -